Custom Search

Tuesday, January 8, 2013

First novel drug approved for treatment of TB in last thirty years.

Bedaquiline approved by us FDA as a new drug for treatment of multi-drug resistant pulmonary tuberculosis (TB).

TB becomes life threatening when the drugs used for treatment develop resistance and are no longer effective or are rendered less effective against the germ Mycobacterium tuberculosis.

US FDA has approved new drug Bedaquiline which is also known as Sirturo which can be used to treat such patients who have developed multi drug resistant pulmonary tuberculosis (TB).

When mycobacterium tuberculosis develops resistance to isoniazid (INH) or rifampicin (RMP) the drugs used as first line of treatment it is called as multi drug resistant pulmonary tuberculosis (TB) . Usual the resistance is developed when cource of drug treatment is interrupted. The drug resistance is attributed to mutation over gene which is responsible for production of ATP, proton pump which is source of energy in the process of replication of Mycobacterium tuberculosis,

Drug Bedaquiline acts by inhabiting enzyme ATP synthase and brings about inhibition of replication of DNA the drug is capable of producing sterilizing effect on Mycobacterium tuberculosis infection. It should be used along with other drugs in treatment.

Bedaquiline is a diarylquinolone compound IUPAC Name (1R,2S)-1-(6-Bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(1-naphthyl)-1-phenyl-butan-2-ol.
It was developed by scientist Koen Andries (University of Antwerp) ; working with Janssen Pharmaceuticals Belgium.

Side effect of the drug Bedaquiline (Sirturo) : It may produce cardiac arrhythmia, drug will be having a warning for this over its pack.

You may also like

New vaccine for TB which can even protect in late stage of infection and in TB infection relapsed form latent Mycobacterium tuberculosis (TB) infection.


No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org